Skip to main content

Ovary

  • Chapter
  • First Online:
  • 2599 Accesses

Abstract

Although the majority of ovarian tumors are ­diagnosed purely on morphologic findings, this chapter identifies specific opportunities for the application of immunohistochemistry to the diagnosis of ovarian surface epithelial tumors, sex cord–stromal tumors, and germ cells tumors. This chapter addresses the use of newer markers such as SALL4 in yolk sac tumors and PAX8 in serous, clear cell and endometrioid carcinomas. Special attention is paid to ovarian versus appendiceal mucinous tumors in pseudomyxoma peritonei, metastatic Krukenberg tumors, and the differential diagnosis of primary and metastatic clear cell tumors. Illustrations demonstrate differential staining patterns such as is seen with p16 in müllerian tumors.

This is a preview of subscription content, log in via an institution.

References

  1. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol. 2005;22(1):3–32.

    Article  PubMed  Google Scholar 

  2. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27(2):161–74.

    PubMed  Google Scholar 

  3. Baker PM, Oliva E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol. 2005;24(1):39–55.

    PubMed  Google Scholar 

  4. Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008;132(3):402–23.

    PubMed  Google Scholar 

  5. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol. 2002;117(6):944–51.

    Article  PubMed  CAS  Google Scholar 

  6. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13(9):962–72.

    Article  PubMed  CAS  Google Scholar 

  7. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992;140(2):427–47.

    PubMed  CAS  Google Scholar 

  8. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol. 1999;52(4):283–90.

    Article  PubMed  CAS  Google Scholar 

  9. Wauters CC, Smedts F, Gerrits LG, Bosman FT, Ramaekers FC. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol. 1995;26(8):852–5.

    Article  PubMed  CAS  Google Scholar 

  10. Riedel I, Czernobilsky B, Lifschitz-Mercer B, et al. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch. 2001;438(2):181–91.

    Article  PubMed  CAS  Google Scholar 

  11. Ordonez NG. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different. Histopathology. 2000;36(5):433–8.

    Article  PubMed  CAS  Google Scholar 

  12. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61(2):152–63.

    Article  PubMed  CAS  Google Scholar 

  13. Manivel JC, Niehans G, Wick MR, Dehner LP. Intermediate trophoblast in germ cell neoplasms. Am J Surg Pathol. 1987;11(9):693–701.

    Article  PubMed  CAS  Google Scholar 

  14. Kalhor N, Ramirez PT, Deavers MT, Malpica A, Silva EG. Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol. 2009;33(4):633–8. doi:10.1097/PAS.0b013e318191f2eb.

    Article  PubMed  Google Scholar 

  15. Southgate J, Harnden P, Trejdosiewicz LK. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol. 1999;14(2):657–64.

    PubMed  CAS  Google Scholar 

  16. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.

    Article  PubMed  CAS  Google Scholar 

  17. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27(1):1–10.

    Article  PubMed  Google Scholar 

  18. Shevchuk MM, Fenoglio CM, Richart RM. Carcinoembryonic antigen localization in benign and malignant transitional epithelium. Cancer. 1981;47(5):899–905.

    Article  PubMed  CAS  Google Scholar 

  19. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32(10):1566–71.

    Article  PubMed  Google Scholar 

  20. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol. 2009;33(3):376–83.

    Article  PubMed  Google Scholar 

  21. O’Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29(8):1034–41.

    PubMed  Google Scholar 

  22. Takeshima Y, Amatya VJ, Kushitani K, Inai K. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol. 2008;130(5):771–9.

    Article  PubMed  CAS  Google Scholar 

  23. Frierson Jr HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34(6):605–9.

    Article  PubMed  CAS  Google Scholar 

  24. Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129(4):592–605.

    Article  PubMed  CAS  Google Scholar 

  25. Lin F, Zhang PL, Yang XJ, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol. 2007;31(3):371–81.

    Article  PubMed  Google Scholar 

  26. Tong GX, Chiriboga L, Hamele-Bena D, Borczuk AC. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol. 2007;20(8):856–63.

    Article  PubMed  CAS  Google Scholar 

  27. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22(10):1203–14.

    Article  PubMed  CAS  Google Scholar 

  28. Maeda D, Ota S, Takazawa Y, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 2009;22(6):824–32.

    PubMed  CAS  Google Scholar 

  29. Boman F, Buisine MP, Wacrenier A, Querleu D, Aubert JP, Porchet N. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study. J Pathol. 2001;193(3):339–44.

    Article  PubMed  CAS  Google Scholar 

  30. Tashiro Y, Yonezawa S, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol. 1994;25(4):364–72.

    Article  PubMed  CAS  Google Scholar 

  31. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53(3):641–51.

    PubMed  CAS  Google Scholar 

  32. Vang R, Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007;31(5):653–63.

    Article  PubMed  Google Scholar 

  33. Tabrizi AD, Kalloger SE, Kobel M, et al. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol. 2010;29(2):99–107.

    Article  PubMed  Google Scholar 

  34. Kappes S, Milde-Langosch K, Kressin P, et al. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer. 1995;64(1):52–9.

    Article  PubMed  CAS  Google Scholar 

  35. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32(4):600–7.

    Article  PubMed  Google Scholar 

  36. Cao D, Guo S, Allan RW, Molberg KH, Peng Y. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol. 2009;33(6):894–904.

    Article  PubMed  Google Scholar 

  37. Cameron RI, Ashe P, O’Rourke DM, Foster H, McCluggage WG. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2003;22(3):272–6.

    Article  PubMed  CAS  Google Scholar 

  38. Kong CS, Beck AH, Longacre TA. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2010;34(7):915–26.

    Article  PubMed  Google Scholar 

  39. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 2010;220(3):392–400.

    PubMed  Google Scholar 

  40. Euscher ED, Malpica A, Deavers MT, Silva EG. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol. 2005;29(8):1074–8.

    PubMed  Google Scholar 

  41. Hashi A, Yuminamochi T, Murata S, Iwamoto H, Honda T, Hoshi K. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003;22(4):374–7.

    Article  PubMed  Google Scholar 

  42. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44(2):109–15.

    Article  PubMed  CAS  Google Scholar 

  43. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32(1):78–91.

    Article  PubMed  Google Scholar 

  44. O’Connell JT, Tomlinson JS, Roberts AA, McGonigle KF, Barsky SH. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol. 2002;161(2):551–64.

    Article  PubMed  Google Scholar 

  45. Carico E, Fulciniti F, Giovagnoli MR, et al. Adhesion molecules and p16 expression in endocervical adenocarcinoma. Virchows Arch. 2009;455(3):245–51.

    Article  PubMed  CAS  Google Scholar 

  46. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006;19(1):97–105.

    Article  PubMed  CAS  Google Scholar 

  47. Staebler A, Sherman ME, Zaino RJ, Ronnett BM. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol. 2002;26(8):998–1006.

    Article  PubMed  Google Scholar 

  48. Lee ES, Leong AS, Kim YS, et al. Calretinin, CD34, and alpha-smooth muscle actin in the identification of peritoneal invasive implants of serous borderline tumors of the ovary. Mod Pathol. 2006;19(3):364–72.

    Article  PubMed  CAS  Google Scholar 

  49. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31(8):1139–48.

    Article  PubMed  Google Scholar 

  50. Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13(1):16–25.

    Article  PubMed  CAS  Google Scholar 

  51. Leroy X, Farine MO, Buob D, Wacrenier A, Copin MC. Diagnostic value of cytokeratin 7, CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma. Histopathology. 2007;51(6):874–6.

    Article  PubMed  CAS  Google Scholar 

  52. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005;36(2):195–201.

    Article  PubMed  CAS  Google Scholar 

  53. Veras E, Deavers MT, Silva EG, Malpica A. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol. 2007;31(5):774–82.

    Article  PubMed  Google Scholar 

  54. Zhao C, Bratthauer GL, Barner R, Vang R. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: a study of 160 cases. Am J Surg Pathol. 2007;31(2):255–66.

    Article  PubMed  Google Scholar 

  55. Engohan-Aloghe C, Aubain Sommerhausen Nde S, Noel JC. Ovarian involvement by desmoplastic small round cell tumor with leydig cell hyperplasia showing an unusual immunophenotype (cytokeratin negative, calretinin and inhibin positive) mimicking poorly differentiated sertoli leydig cell tumor. Int J Gynecol Pathol. 2009;28(6):579–83.

    Article  PubMed  Google Scholar 

  56. Carlson JW, Nucci MR, Brodsky J, Crum CP, Hirsch MS. Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis. Histopathology. 2007;51(3):305–12.

    Article  PubMed  CAS  Google Scholar 

  57. Kommoss F, Oliva E, Bhan AK, Young RH, Scully RE. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod Pathol. 1998;11(7):656–64.

    PubMed  CAS  Google Scholar 

  58. Ordonez NG, Mackay B. Brenner tumor of the ovary: a comparative immunohistochemical and ultrastructural study with transitional cell carcinoma of the bladder. Ultrastruct Pathol. 2000;24(3):157–67.

    Article  PubMed  CAS  Google Scholar 

  59. Logani S, Oliva E, Amin MB, Folpe AL, Cohen C, Young RH. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27(11):1434–41.

    Article  PubMed  Google Scholar 

  60. Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med. 2006;130(11):1725–30.

    PubMed  Google Scholar 

  61. Hart WR. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int. 2005;55(5):231–43.

    Article  PubMed  Google Scholar 

  62. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol. 2005;24(1):4–25.

    PubMed  Google Scholar 

  63. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology. 2005;47(3):231–47.

    Article  PubMed  CAS  Google Scholar 

  64. Prat J. Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol. 2005;18 Suppl 2:S99–111.

    Article  PubMed  Google Scholar 

  65. Hardisson D, Regojo RM, Marino-Enriquez A, Martinez-Garcia M. Signet-ring stromal tumor of the ovary: report of a case and review of the literature. Pathol Oncol Res. 2008;14(3):333–6.

    Article  PubMed  Google Scholar 

  66. Irving JA, Young RH. Microcystic stromal tumor of the ovary: report of 16 cases of a hitherto uncharacterized distinctive ovarian neoplasm. Am J Surg Pathol. 2009;33(3):367–75.

    Article  PubMed  Google Scholar 

  67. Ohishi Y, Kaku T, Oya M, Kobayashi H, Wake N, Tsuneyoshi M. CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. Gynecol Oncol. 2007;107(1):30–8.

    Article  PubMed  CAS  Google Scholar 

  68. Nolan LP, Heatley MK. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol. 2001;20(2):155–9.

    Article  PubMed  CAS  Google Scholar 

  69. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40(9):1213–23.

    Article  PubMed  CAS  Google Scholar 

  70. Farinola MA, Gown AM, Judson K, et al. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol. 2007;26(4):375–82.

    Article  PubMed  Google Scholar 

  71. McCluggage WG, Young RH. Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors). Am J Surg Pathol. 2007;31(4):592–7.

    Article  PubMed  Google Scholar 

  72. Riopel MA, Perlman EJ, Seidman JD, Kurman RJ, Sherman ME. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas. Int J Gynecol Pathol. 1998;17(1):46–53.

    Article  PubMed  CAS  Google Scholar 

  73. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22(1):57–63.

    Article  PubMed  CAS  Google Scholar 

  74. Baker PM, Oliva E, Young RH, Talerman A, Scully RE. Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases. Am J Surg Pathol. 2001;25(5):557–68.

    Article  PubMed  CAS  Google Scholar 

  75. Alenghat E, Okagaki T, Talerman A. Primary mucinous carcinoid tumor of the ovary. Cancer. 1986;58(3):777–83.

    Article  PubMed  CAS  Google Scholar 

  76. Chu PG, Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol. 2004;121(6):884–92.

    Article  PubMed  Google Scholar 

  77. Vang R, Bague S, Tavassoli FA, Prat J. Signet-ring stromal tumor of the ovary: clinicopathologic analysis and comparison with Krukenberg tumor. Int J Gynecol Pathol. 2004;23(1):45–51.

    Article  PubMed  Google Scholar 

  78. Shaco-Levy R, Kachko L, Mazor M, Piura B. Ovarian signet-ring stromal tumor: a potential diagnostic pitfall. Int J Surg Pathol. 2008;16(2):180–4.

    Article  PubMed  Google Scholar 

  79. Irving JA, McCluggage WG. Ovarian spindle cell lesions: a review with emphasis on recent developments and differential diagnosis. Adv Anat Pathol. 2007;14(5):305–19.

    Article  PubMed  Google Scholar 

  80. He Y, Yang KX, Jiang W, Wang DQ, Li L. Sclerosing stromal tumor of the ovary in a 4-year-old girl with characteristics of an ovarian signet-ring stromal tumor. Pathol Res Pract. 2010;206(5):338–41.

    Article  PubMed  Google Scholar 

  81. Matsumoto M, Hayashi Y, Ohtsuki Y, et al. Signet-ring stromal tumor of the ovary: an immunohistochemical and ultrastructural study with a review of the literature. Med Mol Morphol. 2008;41(3):165–70.

    Article  PubMed  CAS  Google Scholar 

  82. McCluggage WG. Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int J Gynecol Pathol. 2006;25(2):101–20.

    Article  PubMed  Google Scholar 

  83. Zhao C, Vinh TN, McManus K, Dabbs D, Barner R, Vang R. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol. 2009;33(3):354–66.

    Article  PubMed  Google Scholar 

  84. Sasano H, Kaga K, Sato S, Yajima A, Nagura H. Adrenal 4-binding protein in common epithelial and metastatic tumors of the ovary. Hum Pathol. 1996;27(6):595–8.

    Article  PubMed  CAS  Google Scholar 

  85. Abd-Elaziz M, Moriya T, Akahira J, Nakamura Y, Suzuki T, Sasano H. Immunolocalization of nuclear transcription factors, DAX-1 and Ad4BP/SF-1, in human common epithelial ovarian tumors: correlations with StAR and steroidogenic enzymes in epithelial ovarian carcinoma. Int J Gynecol Pathol. 2005;24(2):153–63.

    Article  PubMed  Google Scholar 

  86. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol. 1998;29(8):840–5.

    Article  PubMed  CAS  Google Scholar 

  87. Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol. 2005;29(2):143–56.

    Article  PubMed  Google Scholar 

  88. Zhao C, Barner R, Vinh TN, McManus K, Dabbs D, Vang R. SF-1 is a diagnostically useful immunohistochemical marker and comparable to other sex cord-stromal tumor markers for the differential diagnosis of ovarian sertoli cell tumor. Int J Gynecol Pathol. 2008;27(4):507–14.

    Article  PubMed  CAS  Google Scholar 

  89. Zhao C, Bratthauer GL, Barner R, Vang R. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor. Am J Surg Pathol. 2007;31(9):1378–86.

    Article  PubMed  Google Scholar 

  90. Irving JA, Alkushi A, Young RH, Clement PB. Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma. Am J Surg Pathol. 2006;30(8):929–38.

    Article  PubMed  Google Scholar 

  91. Deavers MT, Malpica A, Liu J, Broaddus R, Silva EG. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003;16(6):584–90.

    Article  PubMed  Google Scholar 

  92. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26(11):1477–83.

    Article  PubMed  Google Scholar 

  93. Seidman JD, Abbondanzo SL, Bratthauer GL. Lipid cell (steroid cell) tumor of the ovary: immunophenotype with analysis of potential pitfall due to endogenous biotin-like activity. Int J Gynecol Pathol. 1995;14(4):331–8.

    Article  PubMed  CAS  Google Scholar 

  94. Costa MJ, DeRose PB, Roth LM, Brescia RJ, Zaloudek CJ, Cohen C. Immunohistochemical phenotype of ovarian granulosa cell tumors: absence of epithelial membrane antigen has diagnostic value. Hum Pathol. 1994;25(1):60–6.

    Article  PubMed  CAS  Google Scholar 

  95. Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol. 2005;18 Suppl 2:S81–98.

    Article  PubMed  Google Scholar 

  96. McCluggage WG, Oliva E, Connolly LE, McBride HA, Young RH. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol. 2004;23(4):330–6.

    Article  PubMed  CAS  Google Scholar 

  97. McCluggage WG. Ovarian neoplasms composed of small round cells: a review. Adv Anat Pathol. 2004;11(6):288–96.

    Article  PubMed  Google Scholar 

  98. Horny HP, Marx L, Krober S, Luttges J, Kaiserling E, Dietl J. Granulosa cell tumor of the ovary. Immunohistochemical evidence of low proliferative activity and virtual absence of mutation of the p53 tumor-suppressor gene. Gynecol Obstet Invest. 1999;47(2):133–8.

    Article  PubMed  CAS  Google Scholar 

  99. Costa MJ, Walls J, Ames P, Roth LM. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior. Hum Pathol. 1996;27(3):274–81.

    Article  PubMed  CAS  Google Scholar 

  100. Kuwashima Y, Uehara T, Kishi K, Shiromizu K, Matsuzawa M, Takayama S. Immunohistochemical characterization of undifferentiated carcinomas of the ovary. J Cancer Res Clin Oncol. 1994;120(11):672–7.

    Article  PubMed  CAS  Google Scholar 

  101. Eichhorn JH, Lawrence WD, Young RH, Scully RE. Ovarian neuroendocrine carcinomas of non-small-cell type associated with surface epithelial adenocarcinomas. A study of five cases and review of the literature. Int J Gynecol Pathol. 1996;15(4):303–14.

    Article  PubMed  CAS  Google Scholar 

  102. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166(3):913–21.

    Article  PubMed  CAS  Google Scholar 

  103. Cools M, Stoop H, Kersemaekers AM, et al. Gonadoblastoma arising in undifferentiated gonadal tissue within dysgenetic gonads. J Clin Endocrinol Metab. 2006;91(6):2404–13. doi:10.1210/jc.2005–2554.

    Article  PubMed  CAS  Google Scholar 

  104. Niehans GA, Manivel JC, Copland GT, Scheithauer BW, Wick MR. Immunohistochemistry of germ cell and trophoblastic neoplasms. Cancer. 1988;62(6):1113–23.

    Article  PubMed  CAS  Google Scholar 

  105. Lifschitz-Mercer B, Walt H, Kushnir I, et al. Differentiation potential of ovarian dysgerminoma: an immunohistochemical study of 15 cases. Hum Pathol. 1995;26(1):62–6.

    Article  PubMed  CAS  Google Scholar 

  106. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005;18 Suppl 2:S61–79.

    Article  PubMed  Google Scholar 

  107. Liu A, Cheng L, Du J, et al. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol. 2010;34(5):697–706.

    PubMed  Google Scholar 

  108. Damjanov I, Osborn M, Miettinen M. Keratin 7 is a marker for a subset of trophoblastic cells in human germ cell tumors. Arch Pathol Lab Med. 1990;114(1):81–3.

    PubMed  CAS  Google Scholar 

  109. Dabbs DJ. Diagnostic immunohistochemistry. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2010.

    Google Scholar 

  110. Zynger DL, McCallum JC, Luan C, Chou PM, Yang XJ. Glypican 2 has a higher sensitivity than alpha-fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns. Histopathology. 2010;56(6):750.

    Article  PubMed  Google Scholar 

  111. Cheng L, Zhang S, Talerman A, Roth LM. Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma. Hum Pathol. 2010;41(5):716–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeffrey Prichard .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Prichard, J., Liu, H., Wilkerson, M. (2011). Ovary. In: Lin, F., Prichard, J. (eds) Handbook of Practical Immunohistochemistry. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-8062-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-8062-5_17

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-8061-8

  • Online ISBN: 978-1-4419-8062-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics